A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Sodium phenylbutyrate/ursodoxicoltaurine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Registrational
- Acronyms OLE Phoenix
- Sponsors Amylyx Pharmaceuticals
Most Recent Events
- 13 Jan 2025 Status changed from recruiting to completed.
- 19 Jul 2024 This trial has been discontinued in Portugal , according to European Clinical Trials Database record.
- 02 Oct 2023 According to a Amylyx Pharmaceuticals media release, the company announced that an abstract on data from this study has been accepted for the poster presentation at the hybrid 2023 Northeast ALS Consortium (NEALS) Annual Meeting.